South Korea
· Delayed Price · Currency is KRW Celltrion Pharm Statistics
Total Valuation
Celltrion Pharm has a market cap or net worth of KRW 2.81 trillion.
| Market Cap | 2.81T |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Celltrion Pharm has 41.42 million shares outstanding.
| Shares Outstanding | 41.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.19% |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 6.00% |
| Float | 18.49M |
Valuation Ratios
The trailing PE ratio is 108.68.
| PE Ratio | 108.68 |
| Forward PE | n/a |
| PS Ratio | 10.24 |
| PB Ratio | 9.28 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.63.
| Current Ratio | 1.23 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 4.48 |
| Debt / FCF | -87.93 |
| Interest Coverage | 6.22 |
Financial Efficiency
Return on equity (ROE) is 8.91% and return on invested capital (ROIC) is 3.83%.
| Return on Equity (ROE) | 8.91% |
| Return on Assets (ROA) | 3.41% |
| Return on Capital (ROIC) | 3.83% |
| Revenue Per Employee | 837.59M |
| Profits Per Employee | 79.35M |
| Employee Count | 328 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 4.20 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.32% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +9.32% |
| 50-Day Moving Average | 74,490.00 |
| 200-Day Moving Average | 92,831.26 |
| Relative Strength Index (RSI) | 40.40 |
| Average Volume (20 Days) | 92,387 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celltrion Pharm had revenue of KRW 274.73 billion and earned 26.03 billion in profits. Earnings per share was 624.77.
| Revenue | 274.73B |
| Gross Profit | 80.84B |
| Operating Income | 28.89B |
| Pretax Income | 25.15B |
| Net Income | 26.03B |
| EBITDA | 42.80B |
| EBIT | 28.89B |
| Earnings Per Share (EPS) | 624.77 |
Balance Sheet
The company has 34.63 billion in cash and 191.75 billion in debt, giving a net cash position of -157.12 billion or -3,792.94 per share.
| Cash & Cash Equivalents | 34.63B |
| Total Debt | 191.75B |
| Net Cash | -157.12B |
| Net Cash Per Share | -3,792.94 |
| Equity (Book Value) | 302.75B |
| Book Value Per Share | 7,314.07 |
| Working Capital | 48.92B |
Cash Flow
In the last 12 months, operating cash flow was 28.44 billion and capital expenditures -30.62 billion, giving a free cash flow of -2.18 billion.
| Operating Cash Flow | 28.44B |
| Capital Expenditures | -30.62B |
| Free Cash Flow | -2.18B |
| FCF Per Share | -52.65 |
Margins
Gross margin is 29.43%, with operating and profit margins of 10.51% and 9.47%.
| Gross Margin | 29.43% |
| Operating Margin | 10.51% |
| Pretax Margin | 9.16% |
| Profit Margin | 9.47% |
| EBITDA Margin | 15.58% |
| EBIT Margin | 10.51% |
| FCF Margin | -0.79% |
Dividends & Yields
Celltrion Pharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.23% |
| Shareholder Yield | -0.23% |
| Earnings Yield | 0.92% |
| FCF Yield | -0.08% |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Celltrion Pharm has an Altman Z-Score of 11.76.
| Altman Z-Score | 11.76 |
| Piotroski F-Score | n/a |